Study Title
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Study Details
Description:
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals Clarity Clinical Trials Contactclinicaltrials@claritypharmaceuticals.com
+61 (0) 2 9209 4037
Government Study Link:
NCT06970847 - Click here to see study onClinicalTrials.gov
Drug Details
64Cu-SAR-bisPSMA
Isotope(s):
- COPPER-64
COPPER-64
Radioisotope: Cu-64
Theranostic Role: PET Imaging
T1/2 (Half-Life): 12.7 Hours
Decay Mode: POSITRON β+, BETA, Electron Capture, GAMMA
Energy: 0.65 MeV, Gamma 511 keV
Range: max 2.5mm, mean 0.7mm
Decay Daughters: Ni64 (Stable), Zn64 (Stable)
Status: FDA Approval: DETECTNET®
Target(s):
- PSMA
Ligand: Small Molecules
Chelator: SAR
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
